Jury awards record-setting $110.5M in baby powder lawsuit

ADVERTISEMENT



LIKE Vaxxter on Facebook


Pharma is going to appeal. Surprise. Hopefully, most of you have stopped using this stuff.

According to wsvn.com.

ST. LOUIS (AP) — A St. Louis jury has awarded a Virginia woman a record-setting $110.5 million in the latest lawsuit alleging that using Johnson & Johnson’s baby powder caused cancer.

The jury ruling Thursday night for 62-year-old Louis Slemp, of Wise, Virginia, comes after three previous St. Louis juries awarded a total of $197 million to plaintiffs who made similar claims. Those cases, including the previous highest award of $72 million, are all under appeal.

Slemp, who was diagnosed with ovarian cancer in 2012, blames her illness on her use of the company’s talcum-containing products for more than 40 years. Her cancer has spread to her liver, and she was too ill to attend the trial. About 2,000 state and federal lawsuits are in courts across the country over concerns about health problems caused by prolonged talcum powder use.

Johnson & Johnson, based in Brunswick, New Jersey, said in a statement that it would appeal and disputed the scientific evidence behind the plaintiffs’ allegations. The company also noted that a St. Louis jury found in its favor in March and that two cases in New Jersey were thrown out by a judge who said there wasn’t reliable evidence that talc leads to ovarian cancer.

“We are preparing for additional trials this year and we will continue to defend the safety of Johnson’s Baby Powder,” the statement said.

I’m sure other pharmaceutical companies are ready to cash in on the cancer treatment, though, so a good amount of this judgment ends up right back in their pockets.




LIKE Vaxxter on Facebook


Join the Fight! Sign up today and stay informed!

* indicates required
*Vaxxter.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Vaxxter.com.

Comments

comments